欧康维视提示

本内容仅供医学专业人士使用。如果您是医学专业人士,请点击确认,进入页面;否则请点击退出,返回上一页。
Home/Innovation/Pipeline
覆盖不同阶段

注:

1. Non-infectious uveitis affecting the posterior segment of the eye

2. We acquired Ou Qin from Huonland and are entitled to all drug registration certificates and data related to Ou Qin. We have registered ourselves as the MAH of Ou Qin.

3. We are the exclusive sales agent of Brimonidine Tartrate Eye Drops in Mainland China. Huonland is the drug registrant and registered manufacturer of Brimonidine Tartrate Eye Drops.

4. May not require Phase I and Phase II clinical trials prior to beginning Phase III clinical trials.

5. May not require Phase I clinical trials prior to beginning Phase II clinical trials.

Follow us